|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.395 USD | +1.48% |
|
+4.57% | +33.61% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 12.1x | - | -0.04x | - | - | - | - | 190M | ||
| 36.12x | 21.74x | 0.74x | 13.12x | 26.72x | 27.54x | 0.55% | 1,102B | ||
| 28.52x | 7.21x | -1.9x | 6.55x | 17.81x | 19.67x | 2% | 643B | ||
| 31.52x | 1041.6x | 0.13x | 7.52x | 15.4x | 15.8x | 2.69% | 450B | ||
| 18.05x | 6.71x | 1.05x | 4.49x | 11.1x | 12.46x | 2.95% | 336B | ||
| 21.91x | 6.55x | -48.01x | 5.62x | 13.6x | 14.87x | 2.8% | 288B | ||
| 14.45x | 6.34x | -8.84x | 5.37x | 11.03x | 12.94x | 3.47% | 222B | ||
| 24.08x | 18.48x | 3.25x | 6.37x | 11.22x | 14.58x | 2.74% | 199B | ||
| -48.34x | 8.53x | 0.34x | 5.87x | 32.62x | 64.88x | 2.38% | 169B | ||
| 11.78x | 1.56x | 0.23x | 3.02x | 7.46x | 8.62x | 7.27% | 137B | ||
| 30.03x | 5.99x | 2.22x | 9.18x | 20.72x | 21.59x | -.--% | 133B | ||
| 11.5x | 5.09x | 0.25x | 3.12x | 8.35x | 9.07x | 4.34% | 118B | ||
| 12.85x | 4.62x | 1.23x | 2.81x | 8.23x | 9.32x | 3.48% | 107B | ||
| 11.44x | 1.21x | 3.24x | 2.13x | 6.88x | 7.85x | 5.61% | 104B | ||
| 24.65x | 5.58x | 1.43x | 8.38x | 15.85x | 16.58x | 1.79% | 77.46B | ||
| 21.9x | 1.78x | -0.13x | 1.79x | 8.5x | 14.27x | 0.45% | 57.05B | ||
| 39.41x | 5.34x | 2.07x | 8.91x | 29.68x | 30.58x | 0.48% | 53.81B | ||
| 44.29x | 1.17x | 54.15x | 2.7x | 9.92x | 27.48x | 3.75% | 53.16B | ||
| 18.87x | 1.9x | 4.03x | 3.43x | 12.88x | 14.46x | 2.19% | 43.09B | ||
| Average | 19.22x | 63.97x | 0.81x | 5.58x | 14.89x | 19.03x | 2.72% | 225.87B | |
| Weighted average by Cap. | 23.87x | 119.10x | -2.56x | 7.61x | 17.80x | 20.52x | 2.23% |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
















